Abstract
The efficacy of stem cell transplantation in amyloidosis largely is determined by treatment-related mortality rates (range, 11-25%). Appropriate patient selection is essential to avoid this high mortality rate. Among 271 patients undergoing stem cell transplantation, troponin T was a powerful predictor of treatment-related mortality. Patients with troponin T levels of 0.06μg/L or higher had a day-100 all-cause mortality rate of 28%. Patients with troponin T levels less than 0.06μg/L had a day-100 all-cause mortality rate of 7% (P<0.001). Troponin T levels should be measured in all patients before transplantation. Those with troponin T levels exceeding 0.06μg/L should be considered for less toxic therapies until the clinically optimal use of stem cell transplantation is better defined by randomized clinical trials.
Original language | English (US) |
---|---|
Pages (from-to) | 36-41 |
Number of pages | 6 |
Journal | Leukemia and Lymphoma |
Volume | 49 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2008 |
Keywords
- Amyloidosis
- Multiple myeloma
- Restrictive cardiomyopathy
- Stem cell transplantation
- Troponin T
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research